Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 10, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Biogen’s biologics license application for aducanumab is supported by the phase 3 EMERGE and ENGAGE trials. The company has also requested a priority review designation.
Concluding his discussion on Parkinson disease OFF episodes management, Peter LeWitt, MD, shares practical advice regarding the use of on-demand therapy.
One of the first case-series studies that analyzed children with COVID-19 suggests that SARS-CoV-2 should be considered for differential diagnosis in children presenting with new neurologic symptoms and splenium signal changes on MRI.
Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.
Anup Patel, MD, offers considerations for recent data with adjunctive brivaracetam in pediatric patients with primary generalized seizures or mixed seizure types.